CD7/CD56 myeloid/natural killer acute leukemia represents a novel rare distinct
hematologic neoplasia. 1 According to its immunologic markers, it is classified as an acute …

We report a patient with lung cancer who developed CD56-positive acute lymphoblastic
leukemia. He was referred to our hospital for thrombocytopenia. Atypical cells were found in …

We have identified and characterized a previously unrecognized form of acute leukemia that
shares features of both myeloid and natural killer (NK) cells. From a consecutive series of …

The disease spectrum of natural killer (NK) cell leukemias and lymphomas has recently
been expanding with the continuing evolution in diagnostic concepts. We describe here …

CD56 is a natural killer (NK) cell marker that has been identified in approximately 15–20% of
acute myeloid leukemia (AML) cases, where it has been associated with monocytic …

Expression of CD56, a marker of natural killer (NK) cells, in acute lymphocytic leukemia
(ALL) is rare and, to date, has been described only in non‐B lineage ALL. Among 194 …

Myeloid/natural killer (NK) cell precursor acute leukemia is an entity of acute leukemia
characterized by poor prognosis and a CD7+ CD56+ myeloid antigen+ phenotype without …

We describe a 69-year-old Japanese male with acute leukemia with a CD7+ and CD56+
immunophenotype presenting with multiple lymphadenopathy. He was treated with …

Acute lymphoblastic leukemias with phenotypic characteristics of natural killer cell derived
lineage are extremely uncommon. We identified an ALL with a phenotype consistent with an …

Immature-type natural killer (NK) cell leukemia is rare and heterogeneous, and is variously
classified as myeloid/NK cell precursor acute leukemia, myeloid/NK cell acute leukemia, or …